Forma and Celgene form a protein homeostasis deal
This article was originally published in Scrip
Forma Therapeutics will earn $165 million in revenue by the end of 2013 after raising only $42 million in venture capital funding since its founding in 2008 due to its various partnerships, including a new deal with Celgene.
You may also be interested in...
The firm reorganized to focus on hemoglobinopathies and cancers after Celgene ended a multi-drug partnership. Also, Flagship funds a gene therapy start-up and brings in a business development veteran, Ultragenyx raises $320m in a royalty deal and Paratek secures up to $285m from BARDA.
Cleave Biosciences leads off a recent slate of venture capital financings with $37m to fund ongoing Phase I programs for the lead drug from its protein homeostasis-focused platform.
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.